KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Jeffrey Rothstein, Angela Genge, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chio, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Nissim Sasson, Manabu Hirai, Fumihiro Takahashi, Alejandro Salah, Art Wamil, Stephen Apple

Muscle Nerve 72(3) 433-442

PMID40474686
PMCIDPMC12338024
DOI10.1002/mus.28448
发表日期2025-06-06
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:研究设计图。
摘要

摘要

INTRODUCTION/AIMS: An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is approved in the US for the treatment of amyotrophic lateral sclerosis (ALS). Placebo-controlled clinical trials showed IV edaravone slows the rate of physical functional decline. This study evaluated whether investigational daily dosing displayed superior efficacy vs. approved on/off dosing of edaravone oral suspension, and assessed safety and tolerability, over 48 weeks in patients with ALS. METHODS: Study MT-1186-A02 (NCT04569084) was a multicenter, phase 3b, double-blind, parallel group, superiority study that randomized patients to edaravone oral suspension (105-mg dose) administered Once Daily or the same edaravone oral suspension dose administered according to the approved On/Off regimen including placebo to mimic daily drug dosing. Patients had definite or probable ALS, baseline forced vital capacity ≥ 70%, and baseline disease duration ≤ 2 years. The primary endpoint was a combined assessment of function and survival (CAFS) at week 48, which included change in ALS Functional Rating Scale-Revised (ALSFRS-R) and time to death. RESULTS: CAFS at week 48 indicated Once Daily dosing did not show a statistically significant difference vs. approved on/off dosing (p = 0.777). Both dosing regimens provided comparable change from baseline ALSFRS-R total score to week 48 (least squares mean difference: 0.27 [95% CI -1.43 to 1.97]). Edaravone oral suspension was well tolerated, and no new safety concerns were identified in either group. DISCUSSION: Daily edaravone oral suspension did not show superiority and had equivalent safety and tolerability vs. the approved On/Off regimen, reinforcing the appropriateness of the approved dosing regimen.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Patient disposition. DBT, double‐blind treatment; PK, pharmacokinetic. a One patient randomized to the On/Off treatment group was excluded from the FAS and SAF because the patient did not receive any study treatment. b Patients who enrolled into the extension study, MT‐1186‐A04, were not required to complete the 2‐week safety follow‐up visit.
非 KM Figure
FIGURE 2Effect of edaravone oral suspension across regions in Study MT‐1186‐A02 based on change in ALSFRS‐R total score at Week 48. ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised; BL, baseline; LS, least squares; SD, standard deviation; SE, standard error.
非 KM Figure
FIGURE 3(Post hoc) Effect of edaravone across studies based on change in ALSFRS‐R total score at week 48 [ 4 ]. ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised; BL, baseline; LS, least squares; SD, standard deviation; SE, standard error; Study 19, Study MCI186‐19; Study A02, Study MT‐1186‐A02. Studies MCI186‐19 and MT‐1186‐A02 had different study designs. Some of these differences included different study populations and statistical analysis methods [ 4 ].
非 KM Figure